BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37729520)

  • 1. Role of protein induced by vitamin-K absence-II in transplanted patients with HCC not producing alpha-fetoprotein.
    Lai Q; Ito T; Iesari S; Ikegami T; Nicolini D; Larghi Laureiro Z; Rossi M; Vivarelli M; Yoshizumi T; Hatano E; Lerut J
    Liver Transpl; 2024 May; 30(5):472-483. PubMed ID: 37729520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
    Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study.
    Wang MD; Sun LY; Qian GJ; Li C; Gu LH; Yao LQ; Diao YK; Pawlik TM; Lau WY; Huang DS; Shen F; Yang T
    Int J Surg; 2022 Sep; 105():106843. PubMed ID: 35995351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
    Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
    Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.
    Suehiro T; Sugimachi K; Matsumata T; Itasaka H; Taketomi A; Maeda T
    Cancer; 1994 May; 73(10):2464-71. PubMed ID: 7513601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of PIVKA-II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery.
    Cai Y; Xie K; Adeeb Alhmoud MN; Lan T; Wan H; Hu D; Lan L; Liu C; Wu H
    Cancer Med; 2023 Sep; 12(17):17866-17877. PubMed ID: 37596739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal surveillance of three biomarkers to predict recurrence of hepatocellular carcinoma after radical resection.
    Tong JS; Lu CD; Lu CJ; Zheng S; Mao SQ
    Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1178-1185. PubMed ID: 37577836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporation of protein induced by vitamin K absence or antagonist-II into transplant criteria expands beneficiaries of liver transplantation for hepatocellular carcinoma: a multicenter retrospective cohort study in China.
    Wang K; Dong L; Lu Q; Yang Z; Fan X; Gao F; Ge W; Wang Z; Zhou Z; Lu D; Wei X; Wei Q; Zhuang L; Qin L; Ye Q; Yang J; Dong J; Zheng S; Xu X
    Int J Surg; 2023 Dec; 109(12):4135-4144. PubMed ID: 37988413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.
    Nanashima A; Taura N; Abo T; Ichikawa T; Sakamoto I; Nagayasu T; Nakao K
    Dig Dis Sci; 2011 Oct; 56(10):3086-100. PubMed ID: 21706206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining γ-GT, PIVKA-II, and AFP to predict long-term prognosis in patients with hepatocellular carcinoma after hepatectomy.
    Sun L; Gu M; Cai J; Yang W; Pan B; Wang B; Zhang C; Guo W
    Clin Exp Pharmacol Physiol; 2023 Apr; 50(4):287-297. PubMed ID: 36507841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents.
    Degasperi E; Perbellini R; D'Ambrosio R; Uceda Renteria SC; Ceriotti F; Perego A; Orsini C; Borghi M; Iavarone M; Bruccoleri M; Rimondi A; De Silvestri A; Sangiovanni A; Lampertico P
    Aliment Pharmacol Ther; 2022 Feb; 55(3):350-359. PubMed ID: 34738664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma.
    Villalba-López F; Sáenz-Mateos LF; Sánchez-Lorencio MI; De La Orden-García V; Alconchel-Gago F; Cascales-Campos PA; García-Bernardo C; Noguera-Velasco JA; Baroja-Mazo A; Ramírez-Romero P
    Sci Rep; 2023 Apr; 13(1):5621. PubMed ID: 37024609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.
    Guan MC; Ouyang W; Liu SY; Sun LY; Chen WY; Tong XM; Zhu H; Yang T
    Hepatobiliary Pancreat Dis Int; 2022 Dec; 21(6):559-568. PubMed ID: 35643910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.
    Kim DY; Toan BN; Tan CK; Hasan I; Setiawan L; Yu ML; Izumi N; Huyen NN; Chow PK; Mohamed R; Chan SL; Tanwandee T; Lee TY; Hai TTN; Yang T; Lee WC; Chan HLY
    Clin Mol Hepatol; 2023 Apr; 29(2):277-292. PubMed ID: 36710606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Tumor Markers After Liver Transplantation In Patients With Hepatocellular Carcinoma.
    Lee TY; Choi HJ; Ahn J; Hong TH; You YK
    Transplant Proc; 2022 Mar; 54(2):461-467. PubMed ID: 35168817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.
    Wang Q; Chen Q; Zhang X; Lu XL; Du Q; Zhu T; Zhang GY; Wang DS; Fan QM
    World J Gastroenterol; 2019 Sep; 25(36):5515-5529. PubMed ID: 31576097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
    World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
    Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
    Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
    Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.